Nullifying Tumor Efflux by Prolonged Endolysosome Vesicles: Development of Low Dose Anticancer-Carbon Nanotube Drug
Source abstract
Abstract
As the majority of side effects of current chemotherapies stems from toxicity due to excessive dosing of anticancer drugs, minimizing the amount of drug while maximizing drug efficacy is essential to increase the life-quality of chemotherapy patients. This study demonstrated that the intracellular delivery of amide linked doxorubicin on carbon nanotube can nullify the efflux of cancer cells by achieving prolonged endolysosome delivery and can induce burst release of doxorubicin in an acidic hydrolase environment and, ultimately, can reduce the amount of anticancer drug by 10-fold compared to conventional effective drug dose. The clearance of accumulated carbon nanotubes in the liver was observed after 4 weeks, and analysis of liver toxicity markers showed no significant changes in GOT and GPT levels and release of pro-inflammatory cytokines across both short- and long-term periods.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Nanopore and Nanochannel Transport Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Nano & Advanced Materials Science, Bio-Nano-Information Tech. R/D Center and RIGET, Gyeongsang National University, Jinju 660-701, South Korea
Department of Anatomy, Institute of Health Science and School of Medicine, Gyeongsang National University, Jinju 660-751, South Korea
Department of Pharmacology, Kyungpook National University Medical School, Daegu 700-422, South Korea
Department of Chemical & Biological Engineering, Gyeongsang National University, Jinju 660-701, South Korea
Toxicological Research Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong 363-700, South Korea
References (51)
Show source-provided references
1. Pennock G. D. · J. Natl. Cancer Inst. · 1991 · 83 · 10510.1093/jnci/83.2.105 ↗
2. Martin M. · Ann. Oncol. · 2006 · 17 · 120510.1093/annonc/mdl135 ↗
3. Lindley C. · Cancer Pract. · 1999 · 7 · 5910.1046/j.1523-5394.1999.07205.x ↗
4. Vriesendorp H. M. · Cancer Chemother. Pharmacol. · 1987 · 19 · 27310.1007/BF00261471 ↗
5. Swain S. M. · Cancer · 2003 · 97 · 286910.1002/cncr.11407 ↗
6. Zitvogel L. · Nat. Rev. Immunol. · 2008 · 8 · 5910.1038/nri2216 ↗
7. Longley D. B. · J. Pathol. · 2005 · 205 · 27510.1002/path.1706 ↗
8. Szakacs G. · Nat. Rev. Drug Discovery · 2006 · 5 · 21910.1038/nrd1984 ↗
9. Sridhar R. · J. Natl. Cancer Inst. · 1992 · 84 · 165310.1093/jnci/84.21.1653 ↗
10. Yahanda A. M. · J. Clin. Oncol. · 1992 · 10 · 162410.1200/JCO.1992.10.10.1624 ↗
11. Allen T. M. · Science · 2004 · 303 · 181810.1126/science.1095833 ↗
12. Peer D. · Nat. Nanotechnol. · 2007 · 2 · 75110.1038/nnano.2007.387 ↗
13. Wang F. · ACS Nano · 2011 · 5 · 367910.1021/nn200007z ↗
14. Gao Y. · ACS Nano · 2011 · 5 · 978810.1021/nn2033105 ↗
15. Milane L. · Mol. Pharmaceutics · 2011 · 8 · 18510.1021/mp1002653 ↗
16. Chow E. K. · Sci. Transl. Med. · 2011 · 3 · 73ra21
17. Li R. · ACS Nano · 2010 · 4 · 139910.1021/nn9011225 ↗
18. Arora H. C. · Cancer Res. · 2012 · 72 · 76910.1158/0008-5472.CAN-11-2890 ↗
19. Meng H. · ACS Nano · 2010 · 4 · 453910.1021/nn100690m ↗
20. Abbasi M. · Pharm. Res. · 2011 · 28 · 251610.1007/s11095-011-0480-z ↗
21. Xiong X. B. · ACS Nano · 2011 · 5 · 520210.1021/nn2013707 ↗
22. Aigner A. · J. Biotechnol. · 2006 · 124 · 1210.1016/j.jbiotec.2005.12.003 ↗
23. Lu P. Y. · Adv. Genet. · 2005 · 54 · 117
24. Liu Z. · Nat. Nanotechnol. · 2007 · 2 · 4710.1038/nnano.2006.170 ↗
25. Liu Z. · Cancer Res. · 2008 · 68 · 665210.1158/0008-5472.CAN-08-1468 ↗
26. Liu Z. · Angew. Chem., Int. Ed. · 2009 · 48 · 766810.1002/anie.200902612 ↗
27. Liu Z. · ACS Nano · 2007 · 1 · 5010.1021/nn700040t ↗
28. Tong L. · Nat. Nanotechnol. · 2012 · 7 · 5610.1038/nnano.2011.210 ↗
29. Kam N. · Angew. Chem., Int. Ed. · 2006 · 45 · 57710.1002/anie.200503389 ↗
30. Kostarelos K. · Nat. Nanotechnol. · 2007 · 2 · 10810.1038/nnano.2006.209 ↗
31. Cheng J. · ACS Nano · 2008 · 2 · 208510.1021/nn800461u ↗
32. Schipper M. L. · Nat. Nanotechnol. · 2008 · 3 · 21610.1038/nnano.2008.68 ↗
33. De la Zerda A. · Nat. Nanotechnol. · 2008 · 3 · 55710.1038/nnano.2008.231 ↗
34. Liu Z. · Nat. Protoc. · 2009 · 4 · 137210.1038/nprot.2009.146 ↗
35. Prabaharan M. · Biomaterials · 2009 · 30 · 606510.1016/j.biomaterials.2009.07.048 ↗
36. Zhang X. · Biomaterials · 2009 · 30 · 604110.1016/j.biomaterials.2009.07.025 ↗
37. Min K. H. · J. Controlled Release · 2010 · 144 · 25910.1016/j.jconrel.2010.02.024 ↗
38. Huang W. C. · J. Drug Targeting · 2011 · 19 · 94410.3109/1061186X.2011.632012 ↗
39. Wu W. · ACS Nano · 2009 · 3 · 274010.1021/nn9005686 ↗
40. Fabbro C. · Chem. Commun. (Cambridge, U.K.) · 2012 · 48 · 391110.1039/c2cc17995d ↗
41. Gu Y. J. · Int. J. Nanomed. · 2011 · 6 · 2889
42. Yang R. · J. Am. Chem. Soc. · 2008 · 130 · 835110.1021/ja800604z ↗
43. Chiu C. F. · J. Phys. Chem. A · 2011 · 115 · 957910.1021/jp200152z ↗
44. Ballesteros B. · J. Am. Chem. Soc. · 2007 · 129 · 506110.1021/ja068240n ↗
45. Chidawanyika W. · Carbon · 2010 · 48 · 283110.1016/j.carbon.2010.04.015 ↗
46. Ali-Boucetta H. · Chem. Commun. (Cambridge, U.K.) · 2008 · 45910.1039/B712350G ↗
47. Baskaran D. · J. Am. Chem. Soc. · 2005 · 127 · 691610.1021/ja0508222 ↗
48. Conner S. D. · Nature · 2003 · 422 · 3710.1038/nature01451 ↗
49. Worm J. · J. Biol. Chem. · 2001 · 276 · 3999010.1074/jbc.M103181200 ↗
50. Mutlu G. M. · Nano Lett. · 2010 · 10 · 166410.1021/nl9042483 ↗
51. Cho K. · Clin. Cancer Res. · 2008 · 14 · 131010.1158/1078-0432.CCR-07-1441 ↗